EUR 6m capital increase for KiOmed Pharma

Merodis, a corporate finance consulting firm part of the EuroMerger network, is pleased to disclose that it has assisted KiOmed Pharma for its latest capital increase totalling EUR 6,1m.

KiOmed Pharma is a spin-off from KitoZyme and Liège University (Belgium) developing, producing and marketing ultrapure vegetable-based chitosan and derivatives for high-end medical applications.

Through a series of comparative and pre-clinical studies, KiOmed Pharma has repeatedly demonstrated that its chitosan, a non-cross-linked biocompatible formulation, offers by its design promising additional and tuneable attributes in comparison with hyaluronic acid, whose market is expected to reach EUR 10bn by 2019.